Related references
Note: Only part of the references are listed.Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action
Jeroen J. Lannnerts van Bueren et al.
CANCER RESEARCH (2006)
Treatment of rheumatoid arthritis with rituximab: An update and possible indications
Salvatore De Vita et al.
AUTOIMMUNITY REVIEWS (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
LN Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys
Y Vugmeyster et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Renaissance of cancer therapeutic antibodies
MJ Glennie et al.
DRUG DISCOVERY TODAY (2003)
Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells
T Sieber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect
WK Bleeker et al.
BLOOD (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Signalling antibodies for the treatment of neoplastic disease
MJ Glennie
DISEASE MARKERS (2000)
Share Paper
